HRGN — Harvard Apparatus Regenerative Technology Income Statement
0.000.00%
- $41.81m
- $42.04m
- $0.10m
Annual income statement for Harvard Apparatus Regenerative Technology, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 0 | 0 | 0 | 0 | 0.103 |
Cost of Revenue | |||||
Gross Profit | — | — | — | — | 0.079 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Unusual Expense / Income | |||||
Total Operating Expenses | 8.87 | 5.33 | 8.23 | 6.15 | 9.09 |
Operating Profit | -8.87 | -5.33 | -8.23 | -6.15 | -8.99 |
Total Net Non Operating Interest Income / Expense | |||||
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -8.33 | -4.87 | -7.98 | -6.07 | -8.95 |
Net Income After Taxes | -8.33 | -4.87 | -7.98 | -6.07 | -8.95 |
Net Income Before Extraordinary Items | |||||
Net Income | -8.33 | -4.87 | -7.98 | -6.07 | -8.95 |
Adjustments to Net Income | |||||
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -8.33 | -4.87 | -7.98 | -6.25 | -9.02 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -1.21 | -0.553 | -0.833 | -0.551 | -0.67 |